Drugs / CTO1681
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05905328 | Dec 2023 → Jun 2027 expected | cytokine release syndrome | CytoAgents, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTO1681 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05905328 ↗ |
| Route | Oral | “Participants receive 10 μg CTO1681 orally 3 times daily (total daily dose of 30 μg) for 15 days.” NCT05905328 ↗ |